 WOODCLIFF LAKE, N.J.--BUSINESS WIRE--Eagle Pharmaceuticals, Inc. Nasdaq: EGRX Eagle or the Company today announced financial results for the three months ended March 31, 2021. Business and Recent Highlights: Completed the last study required by FDA for the Companys vasopressin product and expect to have the results shortly. Eagle plans to respond to the CRL issued for its first-to-file Abbreviated New Drug Applicable ANDA for vasopressin in full by mid-year. The Companys patent 